|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0021107,
umls-concept:C0034656,
umls-concept:C0038257,
umls-concept:C0155626,
umls-concept:C0162577,
umls-concept:C0247025,
umls-concept:C0288672,
umls-concept:C0574032,
umls-concept:C1519767,
umls-concept:C1707455
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2008-4-16
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Abciximab infusion and uncoated-stent implantation is a complementary treatment strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST-segment elevation myocardial infarction (STEMI). It is uncertain whether there may be similar benefits in replacing abciximab with high-dose bolus tirofiban. Similarly, the use of drug-eluting stents in this patient population is currently discouraged because of conflicting results on efficacy reported in randomized trials and safety concerns reported by registries.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1538-3598
|
|
pubmed:author |
pubmed-author:BologneseLeonardoL,
pubmed-author:CampoGianlucaG,
pubmed-author:ColangeloSalvatoreS,
pubmed-author:FerrariRobertoR,
pubmed-author:FerrarioMaurizioM,
pubmed-author:MorenoRaulR,
pubmed-author:Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab...,
pubmed-author:NazzaroMarco SMS,
pubmed-author:ParrinelloGiovanniG,
pubmed-author:PasquettoGiampaoloG,
pubmed-author:PercocoGianfrancoG,
pubmed-author:PivaTommasoT,
pubmed-author:PratiFrancescoF,
pubmed-author:RodriguezAlfredo EAE,
pubmed-author:SheibanImadI,
pubmed-author:ValgimigliMarcoM,
pubmed-author:VassanelliCorradoC,
pubmed-author:de CesareNicolettaN
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
16
|
|
pubmed:volume |
299
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1788-99
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18375998-Aged,
pubmed-meshheading:18375998-Angioplasty, Balloon, Coronary,
pubmed-meshheading:18375998-Antibodies, Monoclonal,
pubmed-meshheading:18375998-Drug-Eluting Stents,
pubmed-meshheading:18375998-Female,
pubmed-meshheading:18375998-Humans,
pubmed-meshheading:18375998-Immunoglobulin Fab Fragments,
pubmed-meshheading:18375998-Infusions, Intravenous,
pubmed-meshheading:18375998-Kaplan-Meier Estimate,
pubmed-meshheading:18375998-Male,
pubmed-meshheading:18375998-Middle Aged,
pubmed-meshheading:18375998-Myocardial Infarction,
pubmed-meshheading:18375998-Platelet Aggregation Inhibitors,
pubmed-meshheading:18375998-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:18375998-Stents,
pubmed-meshheading:18375998-Tyrosine
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
|
|
pubmed:affiliation |
Cardiovascular Institute, University of Ferrara, Ferrara, Italy. vlgmrc@unife.it
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
